Cysto-conray side effects by duration, gender and age - a phase IV clinical study of FDA data
Summary:
Side effects are reported by people who take Cysto-conray. Common side effects include anaphylactoid reaction among females and nephrogenic systemic fibrosis among males.
The phase IV clinical study is created by eHealthMe based on 21 reports from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
21 people who take Cysto-Conray and have side effects are studied.
What is Cysto-Conray?
Cysto-conray has active ingredients of iothalamate meglumine. eHealthMe is studying from 21 Cysto-conray users for its effectiveness, alternative drugs and more.
Number of Cysto-conray reports submitted per year:
Cysto-Conray side effects by time on the drug*:
< 1 month:
- Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
- Anhedonia (inability to experience pleasure from activities usually found enjoyable)
- Hypersensitivity
- Nephrogenic fibrosing dermopathy (involves fibrosis of skin, joints, eyes due to kidney disease)
1 - 6 months:
n/a
6 - 12 months:
n/a
1 - 2 years:
n/a
2 - 5 years:
n/a
5 - 10 years:
n/a
10+ years:
n/a
not specified:
- Anaphylactoid reaction (type of anaphylaxis that does not involve an allergic reaction but is due to direct mast cell degranulation)
- Drug ineffective
- Hypothermia (body temperature drops below the required temperature for normal metabolism and body functions)
Cysto-Conray side effects by gender *:
female:
- Anaphylactoid reaction (type of anaphylaxis that does not involve an allergic reaction but is due to direct mast cell degranulation)
- Drug ineffective
- Hypersensitivity
male:
- Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
- Anaphylactoid reaction (type of anaphylaxis that does not involve an allergic reaction but is due to direct mast cell degranulation)
- Anhedonia (inability to experience pleasure from activities usually found enjoyable)
- Nephrogenic fibrosing dermopathy (involves fibrosis of skin, joints, eyes due to kidney disease)
Cysto-Conray side effects by age (0-1 to 60+) *:
0-1:
- Drug ineffective
2-9:
- Anaphylactoid reaction (type of anaphylaxis that does not involve an allergic reaction but is due to direct mast cell degranulation)
10-19:
- Hypersensitivity
20-29:
n/a
30-39:
n/a
40-49:
n/a
50-59:
- Anaphylactoid reaction (type of anaphylaxis that does not involve an allergic reaction but is due to direct mast cell degranulation)
60+:
- Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
- Anhedonia (inability to experience pleasure from activities usually found enjoyable)
- Nephrogenic fibrosing dermopathy (involves fibrosis of skin, joints, eyes due to kidney disease)
* Approximation only. Some reports may have incomplete information.
Do you take Cysto-conray?
Personalize this study to your gender and ageHow to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
How the study uses the data?
The study is based on iothalamate meglumine (the active ingredients of Cysto-conray) and Cysto-conray (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered.
Related studies
Alternative drugs to, pros and cons of Cysto-conray:
- Cysto-conray (21 reports)
All Cysto-conray side effects from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zWho is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Solu-Medrol and Binge Eating - 2 seconds ago
- Efidac 24 Chlorpheniramine Maleate and Fatigue Aggravated - 4 seconds ago
- Viagra and Gangrene - 11 seconds ago
- Heparin and Thirst - Excessive - 23 seconds ago
- Heparin and Polyarthritis - 26 seconds ago
- Marinol and Ditropan drug interaction - 26 seconds ago
- Quinapril vs. Prinzide - 37 seconds ago
- Heparin and Polycythaemia - 38 seconds ago
- Hycodan and Hoarseness Or Changing Voice - 39 seconds ago
- Heparin and Polycystic Ovary Disease - 39 seconds ago